Robert Allen Kaiser

US Patent:

20030003018, Jan 2, 2003

Filed:

Apr 2, 2002

Appl. No.:

10/115870

Inventors:

Mark Stolowitz - Pleasanton CA, US
Robert Kaiser - Bothell WA, US
Leslie Linkkila - Kingston WA, US
Charles Dubuque - Menlo Park CA, US
Michael Baum - Seattle WA, US
Erik Engstrom - Covington WA, US
Stephen Bailey - Seattle WA, US

Assignee:

Prolinx Incorporated - Bothell WA

International Classification:

G01N021/00

US Classification:

422/082050, 422/082110

Abstract:

Instruments and systems for the analysis of molecular interactions with enhanced throughput and ease-of-use. In certain aspects, the systems and instruments include miniaturized SPR-based sensors and novel sensor surface chemistry to provide high-throughput automated instruments and systems for molecular interaction analysis.

US Patent:

55266452, Jun 18, 1996

Filed:

Jul 26, 1995

Appl. No.:

8/506903

Inventors:

Robert M. Kaiser - Napa CA

Assignee:

Powerhouse Diesel Services, Inc. - American Canyon CA

International Classification:

F02D 2302

US Classification:

60611

Abstract:

An excess air control system and method (10) for a dual-fuel or spark ignition gas internal combustion engine (12) is provided. The controller (18) senses the exhaust temperature, senses the air manifold temperature, senses the air manifold pressure, and measures the engine power output of the engine (12). Based on these measurements and engine characterization data, a target air manifold pressure is computed. The target air manifold pressure is compared with the sensed air manifold pressure, and an air blowoff valve coupled to an air bypass line linking the air intake to the turbocharger (36) and the air manifold (40) is either opened or closed to achieve the target air manifold pressure.

US Patent:

20220195425, Jun 23, 2022

Filed:

Mar 14, 2022

Appl. No.:

17/694310

Inventors:

- Stanford CA, US
Ayal Hendel - Stanford CA, US
Joe Clark - Stanford CA, US
Rasmus O. Bak - Stanford CA, US
Daniel E. Ryan - Santa Clara CA, US
Douglas J. Dellinger - Santa Clara CA, US
Robert Kaiser - Santa Clara CA, US
Joel Myerson - Santa Clara CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA
Agilent Technologies, Inc. - Santa Clara CA

International Classification:

C12N 15/11
C12N 9/22
C12N 9/96
C12N 15/90

Abstract:

Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

US Patent:

20220195426, Jun 23, 2022

Filed:

Mar 14, 2022

Appl. No.:

17/694336

Inventors:

- Stanford CA, US
Ayal Hendel - Stanford CA, US
Joe Clark - Stanford CA, US
Rasmus O. Bak - Stanford CA, US
Daniel E. Ryan - Santa Clara CA, US
Douglas J. Dellinger - Santa Clara CA, US
Robert Kaiser - Santa Clara CA, US
Joel Myerson - Santa Clara CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior Univerisity - Stanford CA
Agilent Technologies, Inc. - Santa Clara CA

International Classification:

C12N 15/11
C12N 9/22
C12N 9/96
C12N 15/90

Abstract:

Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

US Patent:

20220195427, Jun 23, 2022

Filed:

Mar 14, 2022

Appl. No.:

17/694361

Inventors:

- Stanford CA, US
Ayal Hendel - Stanford CA, US
Joe Clark - Stanford CA, US
Rasmus O. Bak - Stanford CA, US
Daniel E. Ryan - Santa Clara CA, US
Douglas J. Dellinger - Santa Clara CA, US
Robert Kaiser - Santa Clara CA, US
Joel Myerson - Santa Clara CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA
Agilent Technologies, Inc. - Santa Clara CA

International Classification:

C12N 15/11
C12N 9/22
C12N 9/96
C12N 15/90

Abstract:

Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

US Patent:

20180119140, May 3, 2018

Filed:

Oct 3, 2017

Appl. No.:

15/724073

Inventors:

- Stanford CA, US
Ayal Hendel - Stanford CA, US
Joe Clark - Stanford CA, US
Rasmus O. Bak - Stanford CA, US
Daniel E. Ryan - Santa Clara CA, US
Douglas J. Dellinger - Santa Clara CA, US
Robert Kaiser - Santa Clara CA, US
Joel Myerson - Santa Clara CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Stanford CA
Agilent Technologies, Inc. - Santa Clara CA

International Classification:

C12N 15/11
C12N 9/22
C12N 9/96
C12N 15/90

Abstract:

Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

US Patent:

20160351071, Dec 1, 2016

Filed:

May 5, 2016

Appl. No.:

15/147865

Inventors:

- Dallas TX, US
Robert Cresswell Kaiser - Dallas TX, US

Assignee:

GOPI Corporation - Dallas TX

International Classification:

G09B 19/00
G09B 5/12
G01C 19/5776
G01P 15/08
G01P 1/00

Abstract:

A rigid elongated member with at least a longitudinal curvature and a cushion placed on the concave side of the member. An electronics module is disposed between the cushion and the rigid member and records information about rotation of the member. Data is captured, processed, and may be displayed on a computing device.